Putnam Investments LLC Intercept Pharmaceuticals, Inc. Transaction History

Putnam Investments LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$9.17 - $19.29 $334,796 - $704,277	-36,510 Reduced 28.22%	92,877 $1.03 Million
Q1 2023 May 22, 2023	BUY	$12.53 - $21.71 $1.19 Million - $2.07 Million	95,151 Added 277.93%	129,387 $1.74 Million
Q4 2022 Feb 14, 2023	BUY	$11.61 - $16.11 $28,920 - $40,130	2,491 Added 7.85%	34,236 $423,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $34,078 - $54,982	2,791 Added 9.64%	31,745 $443,000
Q2 2022 Aug 15, 2022	SELL	$11.23 - $19.59 $3,997 - $6,974	-356 Reduced 1.21%	28,954 $400,000

Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $27,943 - $37,181	-2,090 Reduced 6.66%	29,310 $477,000
Q4 2021 Feb 14, 2022	BUY	$14.28 - $19.53 $448,392 - $613,242	31,400 New	31,400 $511,000
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $1.16 Million - $1.59 Million	-19,703 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $511,182 - $793,229	6,573 Added 50.06%	19,703 $1.57 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $1.21 Million - $1.58 Million	13,130 New	13,130 $1.47 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.